Brief: JCR Pharmaceuticals Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA
10/11/2023 13:14
Nov 10 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T :
* JCR PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN A
GLOBAL
PHASE I/II CLINICAL TRIAL OF JR-441 FOR THE TREATMENT OF MPS
IIIA
* JCR PHARMACEUTICALS CO LTD - JCR INTENDS TO START CLINICAL
TRIALS ON FOUR ADDITIONAL PROGRAMS FROM ITS LSD PIPELINE BY
FY2027
Source text for Eikon: ID:nBw61bvxja
Further company coverage: 4552.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results